ArticleJournal of experimental & clinical cancer research : CR2016
Pancreatic cancer cell-derived IGFBP-3 contributes to muscle wasting.
Article in Journal of experimental & clinical cancer research : CR, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Exercise interventions and serum IGF-1 levels in older adults with frailty and/or sarcopenia: a systematic review and meta analysis.Frontiers in public health · 2025Pooled it
- Cancer- and cardiac-induced cachexia: same fate through different inflammatory mediators?Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022Pooled it
- Tumor-induced orexigenic imbalance lowers protein appetite and drives early organ wasting symptoms.Nature communications · 2026Article
- White-to-brown adipose switching promotes bladder cancer progression.Neoplasia (New York, N.Y.) · 2026Article
- Prognostic model for pancreatic cancer based on machine learning of routine slides and transcriptomic tumor analysis.British journal of cancer · 2026Article
- Ablation of tumor-derived IGFBP-3 attenuates cancer-associated skeletal muscle wasting in murine pancreatic cancer.American journal of physiology. Cell physiology · 2026Article
- Pathologic Signaling and Disease Implications of Insulin-like Growth Factor Binding Proteins in Cancer, Cardiovascular Disease, and Fibrosis.International journal of molecular sciences · 2025Review
- Pan-cancer secreted proteome and skeletal muscle regulation: insight from a proteogenomic data-driven knowledge base.Functional & integrative genomics · 2025Review
- Drosophila Intestine as a Model to Study Tumors.Advances in experimental medicine and biology · 2025Review
- Integrated multi-omics profiling to establish an IGFBP-based prognostic score for pancreatic ductal adenocarcinoma: unraveling prognostic biomarkers, immune microenvironment crosstalk, and therapeutic implications.Frontiers in immunology · 2025Article
- Cancer cachexia: multilevel metabolic dysfunction.Nature metabolism · 2024Review
- Oncostatin M signaling drives cancer-associated skeletal muscle wasting.Cell reports. Medicine · 2024Article
- MIIP downregulation drives colorectal cancer progression through inducing peri-cancerous adipose tissue browning.Cell & bioscience · 2024Article
- Gene model for the ortholog ofmicroPublication biology · 2024Article
- Antisense Oligonucleotide-Mediated Downregulation of IGFBPs Enhances IGF-1 Signaling.Journal of neuromuscular diseases · 2024Article
- The uncharacterized transcriptOncotarget · 2023Article
- Tumor Cytokine-Induced Hepatic Gluconeogenesis Contributes to Cancer Cachexia: Insights from Full Body Single Nuclei Sequencing.bioRxiv : the preprint server for biology · 2023Article
- Proposing new early detection indicators for pancreatic cancer: Combining machine learning and neural networks for serum miRNA-based diagnostic model.Frontiers in oncology · 2023Article
- What we have learnt fromHeliyon · 2022Review
- Nutritional and Exercise Interventions in Cancer-Related Cachexia: An Extensive Narrative Review.International journal of environmental research and public health · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 6 institutions in 2 countries.
Funding
Abstract
backgroundProgressive loss of skeletal muscle, termed muscle wasting, is a hallmark of cancer cachexia and contributes to weakness, reduced quality of life, as well as poor response to therapy. Previous studies have indicated that systemic host inflammatory response regarding tumor development results in muscle wasting. However, how tumor directly regulates muscle wasting via tumor-derived secreted proteins is still largely unknown.
methodsIn this study, we performed bioinformatics analysis in two datasets of pancreatic ductal adenocarcinoma, which causes cancer cachexia and muscle wasting with the highest prevalence, and uncovered that IGFBP3, which encodes IGF-binding protein-3 (IGFBP-3), is dramatically up-regulated in pancreatic tumor samples. We also verified the wasting effect of IGFBP-3 on C2C12 muscle cells with biochemical and genetic assays.
resultsIGFBP-3 potently leads to impaired myogenesis and enhanced muscle protein degradation, the major features of muscle wasting, via IGF signaling inhibition. Moreover, conditioned medium from Capan-1 pancreatic cancer cells, which contains abundant IGFBP-3, significantly induces muscle cell wasting. This wasting effect is potently alleviated by IGFBP3 knockdown in Capan-1 cells or IGFBP-3 antibody neutralization. Strikingly, compared to muscle cells, IGF signaling and proliferation rate of Capan-1 cells were rarely affected by IGFBP-3 treatment.
conclusionsOur results demonstrated that pancreatic cancer cells induce muscle wasting via IGFBP-3 production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.